Monitor the Chief Commercial Officer search and any updates on commercial strategy execution. No immediate trading catalyst from this organizational change.
CGON drugs
CGON drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 26 $61.89entry
- T+1 · 6mo ago −1.76%α −1.77% · $60.80
- T+5 · 6mo ago −4.30%α −5.38% · $59.23
- T+20 · 5mo ago +13.50%α +15.45% · $70.25
- T+60 · 3mo ago +30.36%α +27.64% · $80.68
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CG Oncology announced the departure of President & COO Ambaw Bellete, effective June 30, 2026, and appointed CEO Arthur Kuan as President in addition to his existing roles. The company has initiated a search for a Chief Commercial Officer. This is a routine executive reorganization with no material financial impact.
Key Facts
- President & COO Ambaw Bellete agreed to separation effective June 30, 2026
- CEO Arthur Kuan appointed as President in addition to his current positions
- Company initiated search for a Chief Commercial Officer
- Bellete will receive severance benefits per existing employment agreement
Financial Impact
No financial figures disclosed; severance is contractual and routine
Risk Factors
- Potential disruption from COO departure during commercial build-out
- Key-person concentration risk as CEO adds President role
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-237908 |
| Document: 0001193125-26-237908-index-headers.html | 0001193125-26-237908 |
| Document: 0001193125-26-237908-index.html | 0001193125-26-237908 |
| Document: 0001193125-26-237908.txt | 0001193125-26-237908 |
Track record
25 reports on CGON
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
- Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
- Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
- Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
- Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers